Literature DB >> 19968782

Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension.

Mar Coll1, María Martell, Imma Raurell, Nahia Ezkurdia, Silvia Cuenca, Javier Hernández-Losa, Rafael Esteban, Jaume Guardia, Jaume Bosch, Joan Genescà.   

Abstract

BACKGROUND AND AIMS: Portal hypertension is associated with downregulation of mRNA and proteins involved in adrenergic transmission in the superior mesenteric artery (SMA) in portal vein-ligated (PVL) and cirrhotic rats. We aimed to investigate whether SMA adrenergic dysfunction was accompanied by sympathetic nerve structural changes and whether it was extensive to resistance mesenteric arteries. We also attempted to localize the origin of mRNA of specific adrenergic genes. METHODS AND
RESULTS: In situ hybridization showed tyrosine hydroxylase (Th) mRNA expression in neuronal bodies of superior mesenteric ganglia and inside axonal fibres surrounding proximal SMA sections. Comparison of SMA by Th immunohistochemistry, both in PVL and bile duct-ligated (BDL) rats, demonstrated a significant decrease in the number of nervous structures (69% PVL; 62% BDL), total nervous area (70% PVL; 52% BDL) and Th-stained nervous area (89% PVL; 64% BDL) compared with sham rats. A strong correlation was detected between the Th-stained nervous area and the haemodynamic parameters, mainly with SMA resistance (r=0.9, P<0.001 for PVL and r=0.75, P=0.018 for BDL). Western blot analysis of Th, dopamine beta-hydroxylase and synaptosome-associated protein of 25 kDa indicated a significant inhibition in protein expression (35-58%) in mesenteric resistance arteries from both portal hypertension models compared with sham. By contrast, nervous structure analysis and protein expression in renal arteries showed no differences between sham and PVL rats.
CONCLUSION: Portal hypertension is associated with sympathetic nerve atrophy/regression in the mesenteric arterial vasculature that could contribute to the splanchnic vasodilation associated with portal hypertension.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19968782     DOI: 10.1111/j.1478-3231.2009.02176.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  7 in total

1.  Physiopathology of splanchnic vasodilation in portal hypertension.

Authors:  María Martell; Mar Coll; Nahia Ezkurdia; Imma Raurell; Joan Genescà
Journal:  World J Hepatol       Date:  2010-06-27

Review 2.  Pathophysiology of portal hypertension.

Authors:  Yasuko Iwakiri
Journal:  Clin Liver Dis       Date:  2014-02-25       Impact factor: 6.126

3.  Glytan decreases portal pressure via mesentery vasoconstriction in portal hypertensive rats.

Authors:  Qing-Hong Du; Lin Han; Jun-Jie Jiang; Ya Xu; Wei-Hong Li; Peng-Tao Li; Xin-Yue Wang; Xu Jia
Journal:  World J Gastroenterol       Date:  2014-11-28       Impact factor: 5.742

4.  Inhibition of neuronal apoptosis and axonal regression ameliorates sympathetic atrophy and hemodynamic alterations in portal hypertensive rats.

Authors:  Nahia Ezkurdia; Imma Raurell; Sarai Rodríguez; Antonio González; Rafael Esteban; Joan Genescà; María Martell
Journal:  PLoS One       Date:  2014-01-06       Impact factor: 3.240

5.  Differential Sympathetic Vasomotor Activation Induced by Liver Cirrhosis in Rats.

Authors:  Heder F G Estrela; Elaine S Damásio; Eduardo K U N Fonseca; Cássia T Bergamaschi; Ruy R Campos
Journal:  PLoS One       Date:  2016-04-07       Impact factor: 3.240

6.  Decompensated liver cirrhosis and neural regulation of mesenteric vascular tone in rats: role of sympathetic, nitrergic and sensory innervations.

Authors:  Esther Sastre; Laura Caracuel; Isabel Prieto; Pablo Llévenes; M Ángeles Aller; Jaime Arias; Gloria Balfagón; Javier Blanco-Rivero
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

Review 7.  Portal hypertension as immune mediate disease.

Authors:  Sara Manti; Lucia Marseglia; Gabriella D'Angelo; Martina Filippelli; Caterina Cuppari; Eloisa Gitto; Claudio Romano; Teresa Arrigo; Carmelo Salpietro
Journal:  Hepat Mon       Date:  2014-06-07       Impact factor: 0.660

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.